Clinical Validity of the diagnostic criteria for metabolic-associated fatty liver disease: a real-world experience

Introduction

Metabolic associated fatty liver disease (MAFLD) (formerly known as non-alcoholic fatty liver disease) is the most common liver disease that affects about 25–30% of the global population(1–3). The MAFLD is a multisystem disease with wide consequences, as it not only increases the risk of liver cirrhosis and failure and hepatocellular carcinoma (HCC), but also increase the risk for various extra-hepatic complications such as cardiovascular disease, chronic kidney disease, type 2 diabetes, osteoporosis, and some types of cancers(4).

The pathogenesis of the disease is complex and involves a dynamic interaction between environmental factors and genetic basis(5, 6), with evidence of shared genetics between MAFLD and other metabolic diseases(7). Although, classically, linked to obesity, there is an emerging evidence that a considerable proportion of patients are non-obese, as called lean MAFLD (8). However, the characteristics of this group of patients are not well characterised, particularly in Caucasian white population.

Worryingly, the Middle East region has the highest prevalence of MAFLD globally, in parallel with dramatic nutrition transition and high rates of physical inactivity in this region(9, 10). However, the current “anti-definition” and linking to alcohol, the disease with labeling “NAFLD” represents a major lacuna that hinders the clinical and research progress(11).

Adding to the complexity, the Middle East region, and particularly Egypt had one of the highest prevalence of hepatitis C worldwide(12, 13). The current definition of NAFLD that is based on exclusion of other diseases, was very problematic and limits the ability to assess the actual magnitude of both problems and proper management of liver diseases that patients have.

Recently, an international consensus proposed new diagnostic criteria for MAFLD that could potentially help to eliminate the current “anti-definition”(2). The criteria are based on evidence of hepatic steatosis, in addition to one of the following three criteria, namely overweight/obesity, presence of type 2 diabetes mellitus, or evidence of metabolic dysregulation. However, the validity and robustness of these proposed criteria in a real-world cohorts are still unknown.

Thus, in this work, we examined the validity of the proposed criteria for MAFLD in a real-life cohort, characterize the characteristics of lean MAFLD and finally determine the characteristics of patients with MAFLD/HCV dual etiologies. Here, we report that the proposed criteria for diagnosis of MAFLD is well validated and easily applicable and capture the entire spectrum of disease including non-obese subjects.

Methods

Study cohort

This is a prospective two centre cross-sectional study included 242 patients previously diagnosed with non-alcoholic fatty liver disease who met the inclusion criteria were consecutively included in the study. Patients were recruited from the outpatient clinics of Minia University Hospitals and Beni-Suef University Hospitals, Egypt. Individuals with alternative diagnoses were excluded including those with excess alcohol intake (>10 g per day for women; and >20 g per day for men), chronic viral hepatitis (hepatitis B and hepatitis C), decompensated liver disease, known active malignancy or an alternative cause for fatty liver. The validity of the novel criteria proposed by the international expert panel to diagnose MAFLD was investigated (2). The novel criteria for diagnosis of MAFLD are shown in Figure 1. g per day for women; and > 20 g per day for men),

• Download figure
• Open in new tab

Figure 1:

The novel proposed diagnostic criteria for metabolic associated fatty liver disease (Adopted from Eslam M, et al 2020) (2)

To investigate the impact of dual eitology on liver fibrosis, a second cohort of patients with dual pathology HCV and MAFLD criteria was included (n = 78), based on the criteria mentioned above, apart from allowing for including HCV-positive patients.

The study was conducted in accordance to the ethics of good clinical practice and Helsinki Declaration after approval of the local ethical committee. A written informed consent was obtained from all patients.

Results

Discussion

This is the first evaluation of the diagnostic accuracy of the novel criteria proposed by the international expert panel to diagnose MAFLD (2) in a real-world cohort of patients previously diagnosed with NAFLD. We demonstrate that the criteria were easy to apply and fit to the diagnosis in nearly all patients (99%), have an excellent diagnostic property with virtually all patients (99%) were identified, with sensitivity (98.4%) and negative predictive value (96.1%). The fact that there is no need to depend on exclusion of other causes of chronic liver disease enhances the feasibility of these criteria.

The new name, MAFLD, was distinguished by several benefits, including accurate and easy diagnosis of the disease in addition to providing appropriate health care and avoidance of stigmatization, trivialization and proper catalyst to increase funding and heath plan action (11). It was not long before the new nomenclature, MAFLD, was published until the researchers grabbed it. Applying the MAFLD criteria in studying a cohort of patients with COVID-19 infection in China was published recently (17). The investigators found that the presence of MAFLD increased the risk obesity on severity of illness with COVID-19infection. In the same context, other researcher, in a multicenter study, found a severe form of Covid-19 in younger patients with MAFLD in the preliminary analysis (18). This finding was attributed to the systemic and hepatic immune response caused by MAFLD contributing to cytokine storm in patients with COVID-19.

Another intriguing finding in our study, non-obese MAFLD patients represent more than 40% of all patients with a higher ratio than other areas in the world and 12.3% were lean MAFLD. Patients with lean MAFLD have favourable metabolic characteristics and fibrosis scores compared to their obese counterparts. The newly proposed criteria for MAFLD incorporating a consideration of metabolic health would be of highl utility in better characterisation of this group of patients, in a manner extend beyond the measurement of obesity by BMI. From clinical standpoint, the proper identification of non-obese MAFLD is crucial. First, While, a recent study suggested that non obese may even benefit from weight reduction as the obese patients with NAFLD (19), the non-obese especially lean individuals may not be easily convinced with the concept of losing weight and exercise which are of pivotal role in treatment of MAFLD. Secondly non obese individuals are less likely to get much attention from their doctors regarding their fatty liver diseases or associated metabolic dysfunction. Applying the recent proposed MAFLD criteria easily identified these patients with accuracy.

Though the pathogenesis of lean MAFLD is not completely understood, a recent study that is shaped by differential metabolic adaptation, that is mediated by increased bile acids and Farnesoid X receptor (FXR) activity compared to the obese counterparts(20). Lean MAFLD patients also tends to have distinct microbiota profile and frequency of genetic variants, such as Transmembrane 6 superfamily 2 and (TM6SF2) interferon lambda 3 (IFNL3) compared to obese subjects(20–22).

Noticeably, the new MAFLD criteria allowed us to better define patients with dual aetiologies. Herein, we characterised the nature of (MAFLD-HCV) instead of exclusion of HCV in previous NAFLD name leading to a drop of large number of patients with actual metabolic dysfunction especially in countries with high prevalence of HCV like Egypt. When comparing MAFLD patients with patients with dual pathology (MAFLD-HCV) we found not only a significant increase in the metabolic parameters but also a severer fibrosis in patients with dual pathology. This association remained significant after adjusting gender, ALT and AST in multiple regression analysis.

Identification of MAFLD and dual pathologies may lead to a notable change in the liver disease map globally. In a recent report revising data of 2.14 million liver related death, NAFLD was diagnosed in 9% of patients while HCV was diagnosed in 26% and alcoholic liver disease was disease including non-obese subjects and to identify a previously largely overlooked group who are having dual etiologies of MAFLD with other liver diseases.

Identification of MAFLD and dual pathologies may lead to a notable change in the liver disease map globally. In a recent report revising data of 2.14 million liver related death, NAFLD was diagnosed in 9& of patients while HCV was diagnosed in 26& and alcoholic liver disease was diagnosed in 25% who died of chronic liver diseases (23). We think that health care and research could get benefit from distinguishing metabolic associated fatty liver diseases and dual pathologies for better management and decreasing the mortality.

The study could have some limitation, the cohort was recruited in a tertiary centre, so it might be subject of selection bias and lack of liver biopsy hinders the details assessment of histological features. Further studies would be required to ascertain that these proposed criteria would achieve the claimed high utility in other communities with different genetic backgrounds, environmental factors, and health care systems than those in the Egypt.

In conclusion, the diagnostic criteria proposed by the international consensus panel for the diagnosis of MAFLD EDCT are easy to apply, and have excellent diagnostic properties, which make them useful for routine clinical practice, large population-based epidemiological studies or for, clinical trials. In addition, application of these criteria allowed to capture the entire spectrum of disease including non-obese subjects and to identify a previously largely overlooked group who are having dual etiologies of MAFLD with other liver diseases.